Skip to main content
All lobbying clients

AMGEN

Lobbying client · District of Columbia · filed 2025 to 2026

Manufacture Pharmaceuticals

$23,655,000 Reported spend
131 Filings counted
23 Outside firms hired
49 Bills named

Spend is reported income plus in-house expenses across 131 filings. 1 further filing for this client was restated by a later amendment and is left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 24 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as AMGEN INC, AMGEN INC., AMGEN, INC.

 Who filed for this client 24

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings top 30 of 49
  • HR 1
    One Big Beautiful Bill Act
    16 filings
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…
    9 filings
  • HR 5526
    Biosimilar Red Tape Elimination Act
    7 filings
  • HR 3517
    Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
    6 filings
  • S 1040
    A bill to amend title 38, United States Code, to prohibit smoking on the premises of any facility of the Vete…
    6 filings
  • HCONRES 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth…
    6 filings
  • HR 1672
    Maintaining Investments in New Innovation Act
    6 filings
  • HR 946
    ORPHAN Cures Act
    6 filings
  • S 1041
    Affordable Prescriptions for Patients Act
    6 filings
  • HR 1968
    Full-Year Continuing Appropriations and Extensions Act, 2025
    5 filings
  • HR 1574
    RESTORE Patent Rights Act of 2025
    4 filings
  • HR 2214
    DRUG Act
    4 filings
  • HR 3152
    Patent Eligibility Restoration Act of 2025
    4 filings
  • HR 3160
    PREVAIL Act
    4 filings
  • HR 5256
    340B ACCESS Act
    4 filings
  • S 1546
    Patent Eligibility Restoration Act of 2025
    4 filings
  • S 1553
    PREVAIL Act
    4 filings
  • HR 1990
    American Innovation and R&D Competitiveness Act of 2025
    3 filings
  • HR 3269
    ETHIC Act
    3 filings
  • HR 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
    3 filings
  • HR 4317
    PBM Reform Act of 2025
    3 filings
  • HR 6166
    Lowering Drug Costs for American Families Act
    3 filings
  • HR 6485
    Skinny Labels, Big Savings Act
    3 filings
  • S 1954
    Biosimilar Red Tape Elimination Act
    3 filings
  • S 2658
    Medication Affordability and Patent Integrity Act
    3 filings
  • S 3019
    No Big Blockbuster Bailouts Act
    3 filings
  • S 3345
    PBM Price Transparency and Accountability Act
    3 filings
  • HR 1328
    Supply Chain Security and Growth Act of 2025
    2 filings
  • HR 4581
    340B PATIENTS Act of 2025
    2 filings
  • HR 5509
    Safe Step Act
    2 filings
 Reported by year 2 years
  • 2026 $6,763,000 46 filings
  • 2025 $16,892,000 85 filings
 Issues lobbied 13

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 8
  • SENATE 97
  • HOUSE OF REPRESENTATIVES 94
  • Health & Human Services, Dept of (HHS) 23
  • Centers For Medicare and Medicaid Services (CMS) 18
  • Treasury, Dept of 11
  • Executive Office of the President (EOP) 6
  • Office of Management & Budget (OMB) 5
  • Commerce, Dept of (DOC) 1
 Recent filings 132 total
Q2 reportNo activity
MR. DAN CRIPPEN
2nd Quarter 2026 (Apr 1 - June 30) · posted Jul 28, 2026
View →
Q2 report
FEDERAL HEALTH COUNSEL, LLC
2nd Quarter 2026 (Apr 1 - June 30) · posted Jul 21, 2026
View →
Q2 report
TODD STRATEGY GROUP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $80,000 income · posted Jul 20, 2026
View →
Q2 report
THE NICKLES GROUP, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 20, 2026
View →
Q2 report
AMGEN, INC.
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $2,440,000 expenses · posted Jul 20, 2026
View →
Q2 report
SIGHTLINE ADVOCACY, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $20,000 income · posted Jul 20, 2026
View →
Q2 report
AVENUE SOLUTIONS
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026
View →
Q2 report
WILLIAMS AND JENSEN, PLLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 20, 2026
View →
Q2 report
JEFFREY J. KIMBELL & ASSOCIATES, INC.
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $7,500 income · posted Jul 20, 2026
View →
Q2 report
THE MCMANUS GROUP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 20, 2026
View →
Q2 report
BGR GOVERNMENT AFFAIRS
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026
View →
Q2 report
MILLER STRATEGIES, LLC
2nd Quarter 2026 (Apr 1 - June 30) · $60,000 income · posted Jul 20, 2026
View →
Q2 reportNo activity
CAPITOL 6 ADVISORS
2nd Quarter 2026 (Apr 1 - June 30) · $60,000 income · posted Jul 20, 2026
View →
Q2 report
TIBER CREEK GROUP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 19, 2026
View →
Q2 report
MICHAEL J. LAMOUREUX
2nd Quarter 2026 (Apr 1 - June 30) · Senate · $10,000 income · posted Jul 19, 2026
View →
Q2 report
ALPINE GROUP PARTNERS, LLC.
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 17, 2026
View →
Q2 report
TARPLIN, DOWNS & YOUNG, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 16, 2026
View →
Q2 report
CAPITOL COUNSEL LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 16, 2026
View →
Q2 report
CAPITOL TAX PARTNERS, LLP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 16, 2026
View →
Q2 report
EMPIRE CONSULTING GROUP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 16, 2026
View →

Showing the 20 most recent of 132 filings. Search the explorer for "AMGEN".

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem